Green Ralph Elias has reported the acquisition of 12,000 stock options from Vivos Therapeutics, Inc., a significant move that underscores the competitive landscape in the surgical and medical instruments industry.
This acquisition is notable as it reflects a trend among companies in the sector to incentivize key personnel, ensuring that they remain motivated and aligned with the company's long-term goals.
According to the recent SEC filing, Elias received these stock options on September 14, 2026, with an exercise price of $0.18 per share. Following this transaction, Elias now owns a total of 17,200 shares in Vivos Therapeutics.
Background
Green Ralph Elias, identified by CIK 0001835785, is a reporting owner associated with Vivos Therapeutics, Inc. Vivos, which operates under the SIC code for surgical and medical instruments and apparatus, is incorporated in Delaware and has its business address in Littleton, Colorado. The company is publicly traded under the ticker symbol VVOS.
What the Filing Says
The filing details that on September 14, 2026, Elias was granted 12,000 stock options, with one-half vesting immediately and the remainder vesting in two subsequent tranches. The options are valid for a period of ten years from the grant date. The filing notes, "Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised." This indicates Elias's proactive management of his stock options.
Impact
This transaction may influence the internal dynamics at Vivos Therapeutics, as stock options are a common method for aligning the interests of executives and shareholders. The move could also impact employee morale and retention, as it signals the company's commitment to rewarding performance and loyalty.
What's Next
The filing does not say what happens next.